Literature DB >> 12447688

FGFR4 overexpression in pancreatic cancer is mediated by an intronic enhancer activated by HNF1alpha.

Riyaz N H Shah1, J Claire Ibbitt, Kari Alitalo, Helen C Hurst.   

Abstract

Fibroblast growth factor receptor 4 (FGFR4) is expressed in 50-70% of pancreatic carcinomas (PC) and a similar proportion of derived cell lines. Here we determine the sites of FGFR4 transcriptional initiation which show a pattern characteristic of genes with GC-rich, TATA-less promoters. We have examined the chromatin structure around the FGFR4 gene in a panel of expressing and non-expressing PC lines using the DNase I hypersensitive site assay. One region of hypersensitivity, located largely within intron 1, was found to be greatly extended in expressing cells. Subsequent functional analyses using reporter assays demonstrated that this region was able to act as a cell-specific enhancer, only showing significant activity in PC lines expressing endogenous FGFR4. Transcription factors able to bind to the enhancer were investigated using footprinting and mobility shift assays and two binding sites for Sp1 proteins and two sites able to bind hepatic nuclear factor 1 (HNF1) proteins were identified. Further reporter assays using constructs mutated in each binding site demonstrated that HNF1 binding was essential for enhancer activity in expressing cells, an observation that correlated with the increased abundance of HNF1alpha in these same cells as measured by Western blotting. Finally we show that exogenous expression of HNF1 factors in an FGFR4 non-expressing line led to an induction of enhancer activity in reporter assays and also activated expression of the endogenous gene. We conclude that HNF1alpha is a major determinant of FGFR4 expression in PC.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12447688     DOI: 10.1038/sj.onc.1206020

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  22 in total

Review 1.  FGFR4: A promising therapeutic target for breast cancer and other solid tumors.

Authors:  Kevin M Levine; Kai Ding; Lyuqin Chen; Steffi Oesterreich
Journal:  Pharmacol Ther       Date:  2020-05-31       Impact factor: 12.310

2.  Molecular analysis of the first intron in the bovine myostatin gene.

Authors:  Yulong He; Yuehong Wu; Zhigang Lan; Yonggang Liu; Yong Zhang
Journal:  Mol Biol Rep       Date:  2010-12-02       Impact factor: 2.316

3.  FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease.

Authors:  Susana Garcia-Recio; Aatish Thennavan; Michael P East; Joel S Parker; Juan M Cejalvo; Joseph P Garay; Daniel P Hollern; Xiaping He; Kevin R Mott; Patricia Galván; Cheng Fan; Sara R Selitsky; Alisha R Coffey; David Marron; Fara Brasó-Maristany; Octavio Burgués; Joan Albanell; Federico Rojo; Ana Lluch; Eduardo Martinez de Dueñas; Jeffery M Rosen; Gary L Johnson; Lisa A Carey; Aleix Prat; Charles M Perou
Journal:  J Clin Invest       Date:  2020-09-01       Impact factor: 14.808

4.  Hnf1b controls pancreas morphogenesis and the generation of Ngn3+ endocrine progenitors.

Authors:  Matias G De Vas; Janel L Kopp; Claire Heliot; Maike Sander; Silvia Cereghini; Cécile Haumaitre
Journal:  Development       Date:  2015-03-01       Impact factor: 6.868

5.  HNF1alpha is involved in tissue-specific regulation of CFTR gene expression.

Authors:  Nathalie Mouchel; Sytse A Henstra; Victoria A McCarthy; Sarah H Williams; Marios Phylactides; Ann Harris
Journal:  Biochem J       Date:  2004-03-15       Impact factor: 3.857

6.  An endogenous retroviral long terminal repeat is the dominant promoter for human beta1,3-galactosyltransferase 5 in the colon.

Authors:  Catherine A Dunn; Patrik Medstrand; Dixie L Mager
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-08       Impact factor: 11.205

7.  Fibroblast growth factor family aberrations as a putative driver of head and neck squamous cell carcinoma in an epidemiologically low-risk patient as defined by targeted sequencing.

Authors:  Brittny N Tillman; Megan Yanik; Andrew C Birkeland; Chia-Jen Liu; Daniel H Hovelson; Andi K Cani; Nallasivam Palanisamy; Shannon Carskadon; Thomas E Carey; Carol R Bradford; Scott A Tomlins; Jonathan B McHugh; Matthew E Spector; J Chad Brenner
Journal:  Head Neck       Date:  2016-02-05       Impact factor: 3.147

8.  Decreased GLUT2 and glucose uptake contribute to insulin secretion defects in MODY3/HNF1A hiPSC-derived mutant β cells.

Authors:  Chang Siang Lim; Shirley Suet Lee Ding; Yaw Sing Tan; Blaise Su Jun Low; Natasha Hui Jin Ng; Vidhya Gomathi Krishnan; Su Fen Ang; Claire Wen Ying Neo; Chandra S Verma; Shawn Hoon; Su Chi Lim; E Shyong Tai; Adrian Kee Keong Teo
Journal:  Nat Commun       Date:  2021-05-25       Impact factor: 14.919

9.  FGFR4 profile as a prognostic marker in squamous cell carcinoma of the mouth and oropharynx.

Authors:  Roberta Lelis Dutra; Marcos Brasilino de Carvalho; Marcelo Dos Santos; Ana Maria da Cunha Mercante; Diana Gazito; Rafael de Cicco; Gencapo Group; Eloiza Helena Tajara; Iúri Drumond Louro; Adriana Madeira Álvares da Silva
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

10.  G388R mutation of the FGFR4 gene is not relevant to breast cancer prognosis.

Authors:  P Jézéquel; L Campion; M-P Joalland; M Millour; F Dravet; J-M Classe; V Delecroix; R Deporte; P Fumoleau; G Ricolleau
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.